Higher Scientific Officer – Experimental & Translational Theranostic Full Time on the ground NEW

Salary: £39,085 – £50,862 per annum. Commencement on the salary range is subject to comparable skills and experience.

Reporting to: Dr Kathy Chan

Duration of Contract: Fixed Term for 2 years initially, with the possibility of renewal.

Hours per week: 35 hours per week (Full Time)

Location: Sutton

Closing Date: 18th of May 2026. Please note we reserve the right to close this role early if a high volume of suitable applications have been received. This role is eligible for ICR Sponsorship. If this is your first visa in the UK, support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here.

About You

The successful candidate must have a PhD in cancer biology, molecular biology, radiochemistry, medicinal chemistry or a related discipline. A background in in vitro and in vivo radiobiology is essential. Experience in immuno-oncology is desirable.

Department / Directorate Information

The candidate will work in the Experimental and Translational Theranostic Group within the ICR Division of Radiotherapy and Imaging, which provides an integrated environment for multi-modality pre-clinical imaging, co-locating 7T and 1T MRI systems, a PET/SPECT/CT system, multispectral optoacoustic and ultrasound imaging platforms, bioluminescence imaging systems and micro-CT.

What We Offer

• A dynamic and supportive research environment
• Access to state-of-the-art facilities and professional development opportunities
• Collaboration with leading researchers in the field
• Competitive salary and pension

Equal Opportunity

We particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles. We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview.

#J-18808-Ljbffr

Source ⇲